Illinois Faculty Research Gets New Drug Pipeline
Alma Therapeutics, a partnership with Deerfield Management, will evaluate campus translational research starting this fall, with no therapies yet announced.
Updated on Nov. 3, 2026 in Biotech
Live Poll
Do you trust private firms partnering with universities to put patients ahead of profits?
The University of Illinois Urbana-Champaign and healthcare investment firm Deerfield Management launched Alma Therapeutics on November 2, 2026, a translational research partnership. The partnership is announced, not yet producing shipped therapies; it will begin evaluating translational research from Illinois faculty this fall.
Why it matters
The collaboration is designed to move laboratory discoveries from Illinois toward therapeutics by pairing university research with Deerfield's scientific and investment experience. It follows Deerfield's 2024 investment in Excelsior Sciences, a company co-founded by Illinois chemistry professor Martin D. Burke, suggesting a pattern of university-to-industry drug development ties.
The announcement cites a funding horizon of 10 years but no monetary value, so the scale of the commitment cannot be compared against other university-industry partnerships. Deerfield's prior investment in Excelsior Sciences targets automation- and AI-enabled building-block chemistry for small-molecule development, but the source offers no performance figures for that work.
The players
University of Illinois Urbana-Champaign
A public research university whose Carl R. Woese Institute for Genomic Biology hosts Alma Therapeutics and whose faculty supply the translational research to be evaluated.
Deerfield Management
A healthcare-focused investment firm that co-leads Alma Therapeutics and previously invested in Excelsior Sciences.
Martin D. Burke
An Illinois chemistry professor who co-founded Excelsior Sciences, which develops automation- and AI-enabled building-block chemistry for small molecules.
The details
Alma Therapeutics combines laboratory research at the University of Illinois with Deerfield's scientific and investment expertise to convert discoveries into candidate therapeutics. The partnership will be housed in the Carl R. Woese Institute for Genomic Biology and will work with institutes and departments across the university to support drug discovery across disciplines. Its early work will focus on evaluating translational research from Illinois faculty, which means identifying lab findings with potential for development into treatments.
Timeline
2024: Deerfield invested in Excelsior Sciences, co-founded by Martin D. Burke.
November 2, 2026: Alma Therapeutics partnership launched.
This fall: Partnership begins evaluating Illinois faculty translational research.
Over the next 10 years: Deerfield may provide substantial funding.
The Tech Race
Deerfield's 2024 investment in Excelsior Sciences, co-founded by Illinois chemist Martin D. Burke, established an earlier link between the firm and university research in automated small-molecule chemistry. Alma Therapeutics widens that link into a campus-wide program that will screen faculty translational research across Illinois institutes and departments.
For now, the partnership changes nothing for patients, since it has not yet produced any therapy and the source gives no availability or pricing. Faculty at the University of Illinois with translational research are the group that will feel the effect first, as they become candidates for the partnership's evaluation starting this fall.
The takeaway
Watch whether the partnership names the specific therapeutic programs it funds and the size of Deerfield's commitment over the 10-year horizon. Track the first faculty projects selected for evaluation this fall as an early signal of how quickly Illinois lab findings move toward development.
What happens next
This fall, Alma Therapeutics is scheduled to begin evaluating translational research from Illinois faculty, the first concrete step of the partnership.
Further reading
For related coverage, see Biotech developments tied to university research in Champaign.
Source note: This article includes information reported by Pantagraph.
Live Poll
Do you trust private firms partnering with universities to put patients ahead of profits?
